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Abstract
Background: Interleukin-2 (IL-2) induces durable objective responses in a small cohort of patients with
metastatic renal cell carcinoma (RCC) but the antigen(s) responsible for tumor rejection are not known.
5T4 is a non-secreted membrane glycoprotein expressed on clear cell and papillary RCCs. A modified
vaccinia virus Ankara (MVA) encoding 5T4 was tested in combination with high-dose IL-2 to determine
the safety, objective response rate and effect on humoral and cell-mediated immunity.
Methods: 25 patients with metastatic RCC who qualified for IL-2 were eligible and received three
immunizations every three weeks followed by IL-2 (600,000 IU/kg) after the second and third vaccinations.
Blood was collected for analysis of humoral, effector and regulatory T cell responses.
Results: There were no serious vaccine-related adverse events. While no objective responses were
observed, three patients (12%) were rendered disease-free after nephrectomy or resection of residual
metastatic disease. Twelve patients (48%) had stable disease which was associated with improved median
overall survival compared to patients with progressive disease (not reached vs. 28 months, p = 0.0261).
All patients developed 5T4-specific antibody responses and 13 patients had an increase in 5T4-specific T
cell responses. Although the baseline frequency of Tregs was elevated in all patients, those with stable
disease showed a trend toward increased effector CD8+ T cells and a decrease in Tregs.
Conclusion: Vaccination with MVA-5T4 did not improve objective response rates of IL-2 therapy but did
result in stable disease associated with an increase in the ratio of 5T4-specific effector to regulatory T cells
in selected patients.
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Background
Renal cell carcinoma (RCC) is the fifth most common
cancer worldwide and five-year survival is 9% for those
with metastatic disease. High-dose bolus interleukin-2
(IL-2) is associated with a consistent and durable objec-
tive response in 17% of patients with metastatic RCC and
a 6–9% complete response rate [1-3]. The relatively low
frequency of therapeutic responses and significant treat-
ment-associated toxicities, however, has made IL-2 diffi-
cult to recommend for all patients. The objective response
rate to IL-2 was improved in a melanoma clinical trial
when combined with gp100 peptide vaccination resulting
in a 42% objective response rate [4]. In contrast to
melanoma where numerous T cell specific antigens have
been defined, relatively few antigens have been described
in RCC [5].
5T4 is a membrane glycoprotein expressed at high levels
on placental trophoblast and also on a wide range of
human carcinomas including clear cell and papillary RCC
but rarely on normal tissue [6,7]. 5T4 overexpression on
tumor cells has also been associated with metastatic
spread and poor prognosis in cancer patients [8,9]. 5T4 is
not released from the cell membrane and thus can medi-
ate antibody-dependent cell-mediated cytotoxicity
(ADCC). In addition, 5T4-transduced renal carcinoma
cell lines can be recognized by human T cells in vitro, sug-
gesting that 5T4 can induce cellular immunity as well.
5T4-transfected tumor cells display altered morphology
and increased motility suggesting that 5T4 plays a role in
tumor progression and invasion [10]. A recombinant
modified vaccinia virus Ankara (MVA) encoding human
5T4 (MVA-5T4) was tested previously in a phase I clinical
trial for patients with stage IV colorectal carcinoma [11].
Vaccinated patients demonstrated few adverse events and
nearly all patients developed 5T4-specific antibody and T
cell immune responses, which correlated with time to dis-
ease progression [11]. Thus, the expression of 5T4 in RCC,
ability to generate 5T4-specific humoral and cell-medi-
ated immunity and the role of 5T4 in tumor progression
suggest this would be an ideal antigen for targeted immu-
notherapy in RCC. Hence, we sought to determine if vac-
cination with MVA-5T4 could improve the therapeutic
responses observed with standard high-dose IL-2 in
patients with metastatic RCC. In order to take advantage
of IL-2 during the contraction phase of the immune
response, we designed an exploratory trial in which an ini-
tial vaccination was administered alone and subsequent
booster immunizations were supported by the addition of
high-dose bolus IL-2.
Methods
Patients
This phase II trial was an open label study of MVA-5T4
vaccine in patients with metastatic clear cell or papillary
RCC eligible for high-dose IL-2. A total of 25 patients were
enrolled who met these criteria: Eastern Cooperative
Oncology Group (ECOG) performance status of 0 to 1,
life expectancy greater than six months, 18 years of age or
older; able to provide written informed consent; able to
comply with study procedures, hemoglobin > 10 g/dL,
granulocyte count > 1500/mm3, lymphocyte count >
1000/mm3, platelet count > 100,000/mm3, serum creati-
nine < 2.5 mg/dL, total bilirubin < 1.5 × the normal upper
limits, and AST, ALT, and alkaline phosphatase < 3 × the
normal upper limit, or < 5 × the normal upper limit if due
to liver metastases. The clinical protocol was approved by
the Institutional Review Board.
Vaccine preparation
5T4-MVA vaccine was produced by homologous recombi-
nation of human 5T4 cDNA into deletion region III of
MVA under the control of the modified H5 promoter, as
previously described [12]. Individual vials were stored in
a secured, monitored, alarmed refrigerator at -80°C. A
sterile syringe was used to inject 1 mL of solution subcu-
taneously in the deltoid region.
Study design
A dose of 5 × 108 pfu (1 ml) MVA-5T4 was established as
safe in a Phase I trial [11]. In this trial, the first dose was
given by intramuscular injection alone and booster vacci-
nation was given 3 weeks later, followed immediately by
high dose IL-2 (600,000 IU/kg) given every 8 hours up to
a maximum of 15 doses. Three weeks later patients
received a third booster and second cycle of IL-2. All
patients underwent re-staging CT scans two weeks later.
Clinical responses were determined by RECIST criteria
[13]. For patients without progression an additional two
cycles of vaccine/IL-2 were given at three week intervals.
Patients demonstrating benefit after completing two
courses of IL-2 were allowed to continue vaccination every
three months for up to one year. In order to monitor the
immune responses prior-, during- and post-vaccinations,
heparinized blood was collected and processed by centrif-
ugation through Histopaque columns to isolate periph-
eral blood mononuclear cells (PBMC).
Antibody responses
MVA- and 5T4-specific antibody titers were determined by
ELISA as described previously [11]. All test plasma was
compared against a pool of plasma taken from 50 healthy
(vaccinia naïve) donors. Antibody titers were defined as
the greatest dilution of plasma at which the mean optical
density (O.D.) of the test plasma was ≥ 2 fold the mean
O.D. of the negative control (normal human plasma) at
the same dilution. A positive response was defined as a
post-vaccination titer ≥ 2 fold of the baseline titer.Journal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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T cell responses
The IFN-γ ELISPOT was used to monitor T cell responses,
as previously described [14]. Briefly, frozen PBMCs were
thawed and incubated in medium overnight at 37°C, 5%
CO2 prior to use. ELISPOT plates (PVDF, Millipore) were
coated with an anti-IFN-γ capture antibody (human IFN-γ
ELISPOT kit, Mabtech). Following blocking, 2 × 105
PBMCs were added to each well and incubated overnight
at 37°C, 5% CO2 with the appropriate antigens. For posi-
tive control CEF (CMV, EBV and Flu virus) 10 amino acid
length peptides were used. Subsequently, spots were enu-
merated using an automated ELISPOT plate reader. The
precursor frequency was calculated as the number of spot-
forming units from wells containing PBMC and 5T4 over-
lapping peptides after subtraction of the background
(PBMC alone) relative to the number of PBMC seeded per
well. A positive ELISPOT response was reported if the
mean spot forming units (SFU) per well in response to
antigen was ≥ 3 fold the mean SFU/well in wells contain-
ing medium alone and the mean SFU/well in response to
antigen was ≥ 10. A positive response was also required to
demonstrate ≥ 2 fold increase after vaccination. Pheno-
typic characterization was done by four color flow cytom-
etry analysis of PBMC using the following antibodies:
CD4, CD8, CD25, CCR7, CD45RA, Foxp3, GITR, PD-1,
IL-10, CD152, CD107a, granzyme B and perforin. Isotype
matched controls were always included. The change of fre-
quency for specific subset of cells during the post-vaccina-
tion period is calculated by subtracting the basal value of
pre-vaccination time point. Flow cytometry was done
using a FACSCalibur flow cytometer equipped with Cel-
lQuest Pro software. T cell function was tested by mixed
lymphocyte proliferation assay, as previously described
[15]. A total of 16 healthy donor PBMC were used as nor-
mal controls.
Statistical analysis
Since this was an exploratory study, no formal power cal-
culations were undertaken. The intention-to-treat popula-
tion included all subjects enrolled in the study and the
per-protocol population met all eligibility criteria and
completed at least five vaccinations. All safety and efficacy
analyses were carried out using the intention-to-treat
(ITT) population and analysis of immune response was
carried out in the per-protocol population. Descriptive
statistics were analyzed using Student's t-test to assess dif-
ferences between the different study groups with p < 0.05
considered significant. Correlations between variables
were assessed with adjustments to other variables via lin-
ear models. Overall survival (OS) was calculated by the
method of Kaplan-Meier, log rank test. OS was calculated
from the first date of treatment to date of death, or last
known date alive.
Role of funding source
This work was supported by grants from Oxford Biomed-
ica. The funding sources had no role in the study design,
collection, analysis, or interpretation of the data, or in the
writing of the report. They also had no access to the raw
Table 1: Patient characteristics and treatments
Mean age 58.4 (range 44–77)
N = 25 %
Sex Male 17 68
Female 8 32
TNM Stage T X 4 16
00 0
141 0
272 8
372 8
431 2
NX 0 0
01 87 2
10 0
272 8
M0 0 0
12 5 1 0 0
Histology Clear cell 21 84
Papillary 4 16
Sites of disease Lung 16 64
Lymph node 9 36
Soft tissue 7 28
Bone 6 24
Kidney 5 20
Liver 5 20
Pancreas 2 8
Adrenal 1 4
Prior Therapy Nephrectomy 23 92
Chemotherapy 8 32
Immunotherapy 10 40
Radiation therapy 2 8
Cryoablation 1 4
Laser ablation 1 4
Treatment Characteristics
Vaccination ≤ 23 1 2
3–5 14 56
≥ 68 3 2
No. of IL-2 Cycles 1 4 16
29 3 6
30 0
49 3 6Journal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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data. The corresponding author had full access to all data
and the final responsibility to submit for publication.
Results
Patient characteristics
Twenty five patients were enrolled in the trial and
included in the ITT population. One patient withdrew
from the trial early due to relocation and one patient
could not tolerate IL-2, leaving 23 patients in the per-pro-
tocol analysis. The mean age of the ITT population was
58.4 ± 10 years (range 44 – 77 years). 21 patients had clear
cell carcinomas and 4 patients had papillary histology.
Further characteristics are detailed in Table 1.
Treatment-related toxicity
Table 2 shows all adverse events; there were no serious
adverse events related to the vaccine in the ITT popula-
tion. The most frequent side effect related to vaccine
administration was fever in 8 patients. Other toxicities
were largely expected high-dose IL-2 related side effects
(see Table 2).
Humoral immune responses
MVA- and 5T4-specific antibody responses were moni-
tored by ELISA at each sampling time point throughout
the trial and expressed as a titer [see Additional file 1]. All
patients showed an increase in MVA antibody titers fol-
Table 2: Adverse events related to vaccine and IL-2
Vaccine-related AEs Maximum Grade Patients
System Adverse Events N = 25 %
Constitutional Fever 1 8 32
Pain at injection site 1 4 16
Injection site reaction 1 3 12
Myalgia 1 1 4
Chills 1 1 4
IL-2-related AEs
Cardiovascular Cardiopulmonary arrest 4 1 4
Elevated troponin 4 1 4
Hypotension 4 9 36
Ventricular tachycardia 3 1 4
Acidosis 4 1 4
Electrolyte Hyperglycemia 3 4 16
Hypocalcemia 3 1 4
Hyponatremia 3 11 44
Hypophosphatemia 3 3 12
Gastro-intestinal Ischemic bowel 4 1 4
Hematologic Anemia 3 2 8
Neutropenia 3 1 4
Thrombocytopenia 3 4 16
Hepatic Elevated transaminases 3 1 4
Hyperbilirubinemia 3 3 12
Neurologic Confusion 3 3 12
Syncope 3 2 8
Pulmonary Dyspnea 3 1 4
Renal Elevated creatinine 3 22 88
Oliguria 3 2 8
Systemic Fatigue 3 1 4Journal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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lowing vaccination (range, 4000 to 128,000). One patient
(#19) had detectable MVA-specific titers prior to the first
vaccine and this increased further following vaccination.
All patients also demonstrated 5T4-specific antibody titers
ranging from 20 to 2560, which were evident after ≥ 2 vac-
cinations in most patients. Two patients (#13 and 23) had
detectable 5T4-specific antibody titers prior to vaccination
but showed an increase in post-immunization titers.
Effector and regulatory T cell responses
5T4-specific CD8+ T cell responses were monitored by
IFN-γ ELISPOT assay using overlapping 5T4 peptides and
full-length protein. Before immunization only a single
patient had a detectable T cell response (frequency
1:5,618). Following treatment 13 of 23 tested patients
(57%) had detectable 5T4-specific CD8+ T cell responses
with precursor frequencies ranging from 1:21,277 to
1:1,792 (Table 3). Only 3 of 11 (27%) patients with pro-
gressive disease exhibited an increase in T cell response
compared to 10 of 12 patients (83%) with stable disease
(Fig. 1). Positive T cell responses to MVA and a control
CEF peptide pool were detected in all 23 evaluable
patients (Table 4). The CEF-specific precursor frequencies
were highly consistent throughout the study period. The
mean frequency of MVA-specific T cells was decreased
slightly from 1:615 PBMCs pre-vaccination (1.62%) to
1:945 PBMCs post-vaccination (0.105%).
CD8+ effector T cell response were also characterized by
staining for T cell activation markers [16,17]. The mean
frequency of CD8+CD107a+ T cells at baseline was 1.80%
± 0.95 and increased to 2.10% ± 0.64 after vaccination.
Figure 2A shows that patients with stable disease had a sig-
nificantly greater increase in CD8+CD107a+ T cells com-
pared to those with progressive disease (1.50% ± 0.72 vs.
2.09% ± 0.30, p = 0.015). There was also a higher fre-
quency of CD8+perforin+ T cells in RCC patients com-
pared to normal healthy donors (27.58 vs. 15.25%, p =
0.020) and a trend towards decreasing CD8+perforin+ T
cells in patients with progressive disease (Fig. 2B). In addi-
5T4-specific T cell responses in patients with (A) progressive disease and (B) stable disease Figure 1
5T4-specific T cell responses in patients with (A) progressive disease and (B) stable disease.Journal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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tion, there was a significant increase in PD-1 expressing
CD4+ (p = 0.0329 at 3 weeks and p = 0.0281 at 9 weeks)
and CD8+ T cells (p = 0.0373 at 3 weeks) in patients with
progressive disease compared to stable patients (Fig. 2C).
CD4+CD25+FoxP3+ Tregs were monitored by flow
cytometry throughout the trial and functional suppres-
sion determined by co-culture proliferation assay. The
mean frequency of Tregs in the per-protocol population at
baseline was significantly higher than that detected in
healthy donors (6.54% vs. 1.42%, p = 0.00002), although
the degrees of suppression in proliferation assays was sim-
ilar (p = 0.80) (data not shown). In patients with progres-
sive disease, the mean Treg frequency was 7.03% (± 3.21)
before treatment and increased to 8.00% (± 6.93) after
treatment (Fig. 2D). In contrast, patients with stable dis-
ease had a mean Treg frequency of 5.93% (± 1.90) prior to
treatment which decreased to 5.60% (± 2.43) by 15 weeks
(Fig. 2D). The absolute number of Tregs was decreased by
50% in stable patients following treatment (p = 0.006).
Fig. 3E–G shows the kinetics of effector CD8+ T cell
responses and Treg frequency in three representative
patients with stable disease. The effector/regulatory T cell
ratio decreased in patients with progressive disease,
whereas stable patients showed a dramatic increase which
was maintained for up to 24 months (Fig. 3H).
Clinical response
There were no objective responses based on the first re-
staging CT scans. Twelve of 23 (52%) per-protocol
patients, however, had stable disease and went on to a sec-
ond course of vaccination/IL-2. Three patients (13%) were
rendered disease free through surgical resection; 2 patients
had complete regression of all metastatic disease (lungs
and bone) at initial follow-up and underwent nephrec-
tomy of primary tumors, 1 patient had two intra-abdom-
inal masses that regressed by < 20% but were surgically
resected (pathology showed tumor with significant necro-
sis in one mass and no viable tumor in the other). The
median progression-free survival of the per-protocol
patients was 4.76 months and median overall survival has
not yet been reached (Fig. 4A) at a median follow-up of 20
months.
Median overall survival of the 12 stable patients has not
yet been reached (8–32 months) and was 28 months (2–
28 months) for those with progressive disease (Fig. 4B, p
= 0.0206).
Discussion
This study established the safety and feasibility of com-
bining vaccination with MVA expressing 5T4 and high-
dose IL-2 in patients with metastatic RCC. The trial was
Table 3: Antigen specific T cell responses
Patient Number Peak 5T4 polyclonal precursor frequencies ORR (month)
Time point (week) Peptides alone Time Point (week) Protein + Peptides
1 - < 1/200,000 - < 1/200,000 PD
2 - < 1/200,000 3 1/19,231 PD
3 - < 1/200,000 - < 1/200,000 PD
55 5 1/12,048 55 1/1,701 Surgical CR(50+)
62 6 1/21,277 26 1/21,277 SD (13)
72 9 1/2,113 29 1/2,113 SD (9)
8 - < 1/200,000 - < 1/200,000 PD
9 105 1/993 105 1/993 Surgical CR(54+)
10 - < 1/200,000 - < 1/200,000 PD
11 - < 1/200,000 9 1/12,500 SD (2)
12 - < 1/200,000 - < 1/200,000 PD
13 15 1/11,765 15 1/11,765 SD (1)
14 - < 1/200,000 - < 1/200,000 PD
15 - < 1/200,000 92 1/19,231 SD (18)
16 - < 1/200,000 - < 1/200,000 SD (2)
17 78 1/7,042 78 1/4,132 SD (16)
19 - < 1/200,000 20 1/20,833 SD (5)
20 - < 1/200,000 - < 1/200,000 PD
21 - < 1/200,000 - < 1/200,000 PD
22 9 1/12,821 9 1/12,821 PD
23 - < 1/200,000 - < 1/200,000 Surgical CR (13+)
24 - < 1/200,000 6 1/12,048 SD (3.5)
25 - < 1/200,000 3 1/18,868 PD
The peak 5T4 specific responses detected at any time point to 5T4 peptides or 5T4 peptide plus protein. *; no detection of 5T4 responses. Positive 
responses are indicated as bold type.Journal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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initially designed to determine the impact of combination
treatment on objective response rate since there is a well-
defined, consistent response for IL-2 alone [1,2]. We did
not, however, observe any objective responses by strict
RECIST criteria although three patients were rendered dis-
ease free by additional surgery. The reasons for this out-
come might relate to the study design in which we
evaluated initial tumor responses two weeks after com-
pleting the first course of IL-2, selected in order to con-
tinue booster immunizations in a timely manner. Recent
reports suggest that the kinetics of immunotherapy may
require more time to mediate tumor regression in patients
with established disease and, therefore, detection of
tumor regression may be delayed [18,19]. This possibility
Table 4: T cell responses to CEF and MVA antigens by IFN-γ ELISPOT
Patient Number Antigen Peak Ag Specific T cell Precursor Frequencies
Pre Post
1 CEF ND 1/1,299
MVA ND 1/11,364
2 CEF ND 1/10,929
MVA ND 1/4,926
3 CEF ND ND
MVA 1/18,182 1/10,341
5 CEF ND 1/1,658
MVA ND 1/3,993
6 CEF < 1/200,000 < 1/200,000
MVA 1/4,411 1/2,629
7 CEF ND 1/2,084
MVA ND 1/1,935
8 CEF 1/1,613 1/1,126
MVA < 1/200,000 1/1770
9 CEF 1/1,040 1/956
MVA 1/5,263 1/1,452
10 CEF < 1/200,000 < 1/200,000
MVA < 1/200,000 1/3,442
11 CEF 1/5,882 1/2,362
MVA 1/3,030 1/2,135
12 CEF ND < 1/200,000
MVA < 1/200,000 1/45455
13 CEF < 1/200,000 < 1/200,000
MVA < 1/200,000 1/29,630
14 CEF 1/631 1/619
MVA 1/928 1/2,112
15 CEF 1/1,357 1/1,445
MVA 1/3,731 1/2,901
16 CEF 1/2,070 1/2,316
MVA 1/2,618 1/2,685
17 CEF ND 1/10,216
MVA ND 1/5,405
19 CEF 1/1,543 1/2,335
MVA 1/5,618 1/2,273
20 CEF < 1/200,000 < 1/200,000
MVA 1/868 1/984
21 CEF < 1/200,000 < 1/200,000
MVA 1/1,230 1/945
22 CEF ND 1/1,789
MVA ND 1/1,988
23 CEF 1/629 1/1,056
MVA 1/5,208 1/4,561
24 CEF 1/870 1/1,078
MVA 1/1,923 1/23,256
25 CEF 1/1,538 1/1,161
MVA 1/7,143 1/3,697
Abbreviation: ND, not detectedJournal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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is supported by patient #17, who continues to have a slow
but steady regression of tumor over a 24 month period.
Thus, our decision to scan at two weeks might have pre-
vented some patients with stable disease from becoming
objective responders. The trial was also biased by the early
surgical intervention in three patients who were rendered
disease free prior to further follow-up imaging. Two of
these patients had complete regression of metastatic dis-
ease but had large primary renal tumors in place. Primary
tumors are known to be more resistant to immunotherapy
and often require nephrectomy before or after treatment
to optimize response [20]. We also included four patients
with papillary histology in the trial since these tumors
express 5T4, but these tumor are also more resistant to IL-
2, which may have influenced our results [21].
MVA-5T4 vaccine and high-dose IL-2 elicited 5T4-specific
humoral and cell-mediated immunity. All patients devel-
oped an increase in 5T4 antibody titers after vaccination,
consistent with previous clinical trials in patients with
metastatic colorectal and hormone-refractory prostate
cancer [11,22]. While the pattern of antibody response in
our patients was similar to that observed in previous stud-
ies, the magnitude of the response was higher in this trial
(mean 220, maximum titer 2560) compared to colorectal
cancer patients treated with MVA-5T4 and chemotherapy
(mean 76, maximum titer 1280) [14]. We also observed
the induction of 5T4-specific CD8+ T cell responses in
57% (13/23) of vaccinated patients and this compares
favorably to previous trials [11,14]. The induction of
humoral and T cell immunity in this trial might relate to
the underlying tumor histology, since RCC is known to be
more immunogenic than other tumors [23,24] or could
be due to the adjuvant effects of high-dose IL-2. We fur-
ther characterized the effector CD8+ T cells in whole
PBMC and found that there was an increase in CD107a, a
marker of degranulation and cytotoxic function [16,17].
These cells remained elevated in patients with stable dis-
ease but began to decrease at 12 weeks in patients with
progressive disease. We saw a similar trend in CD8+per-
forin+ T cells although this was only significant at 15
weeks. We also found that PD-1 expression, a pan T cell
Characterization of T cell responses Figure 2
Characterization of T cell responses. (A) CD8+CD107a+ effector cells, (B) CD8+perforin+ effector cells, (C) PD-1+ T 
cells, (D) CD4+CD25+FoxP3+ Tregs before and after treatment.Journal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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co-inhibitory receptor, was significantly elevated in both
CD4+ and CD8+ T cells in patients with progressive dis-
ease [25-27]. These data suggest that the loss of effector
CD8+ T cells or decreased effector function is associated
with tumor progression.
Since Tregs may suppress tumor rejection by effector T
cells and because IL-2 can promote Treg activity, we eval-
uated the frequency and functional activity of Tregs in our
patients. We previously reported that Tregs are increased
in metastatic RCC patients but decreased to normal levels
in those patients responding to IL-2 therapy [15]. In the
current study, we similarly found that the Treg population
was increased in patients compared to normal donors
without detectable differences in suppressor activity.
Patients who achieved stable disease demonstrated a 50%
reduction in the mean number of Tregs within four weeks
of completing the first course of IL-2 (p = 0.006) and sup-
ports the notion that patients destined to respond to
immunotherapy exhibit a decreased frequency of Tregs. In
murine tumor models, the ratio of effector to regulatory T
cells was found to be the critical determinant of tumor
regression or progression [28]. Similarly, we found that
patients with stable disease exhibited an increase in the
effector to regulatory ratio that persisted for at least 24
months; in contrast, patients with progressive disease
showed a low ratio at all time points tested. Although we
lacked statistical power in our trial to directly compare
these groups, these data would support determining the
effector to regulatory ratio in future clinical trials.
In summary, this study provides safety and feasibility data
supporting the combination of MVA-5T4 vaccine and IL-
2 for patients with metastatic RCC. The treatment regimen
was associated with induction of 5T4-specific humoral
and cellular immunity. Twelve patients had stable disease,
which was associated with increased effector T cells,
reduced Tregs and increased effector to regulatory T cell
Representative effector CD8+ T cell and Treg responses in 3 patients (A-C) Figure 3
Representative effector CD8+ T cell and Treg responses in 3 patients (A-C). effector/regulatory T cell ratio in all 
patients (D). SD, stable disease (open square), PD, progressive disease (closed square).Journal of Translational Medicine 2009, 7:2 http://www.translational-medicine.com/content/7/1/2
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ratios, suggesting a benefit from therapy. Although there
was insufficient power to make conclusions regarding
clinical response, these data suggest that stable disease by
current RECIST criteria might harbor subsets of patients
who may benefit from immunotherapy. Future rand-
omized studies will be helpful in better delineating the
potential effectiveness of MVA-5T4 and IL-2 for the treat-
ment of RCC.
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